0001520138-23-000124.txt : 20230306 0001520138-23-000124.hdr.sgml : 20230306 20230306080012 ACCESSION NUMBER: 0001520138-23-000124 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20230302 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20230306 DATE AS OF CHANGE: 20230306 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOVIE INC. CENTRAL INDEX KEY: 0001580149 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 462510769 STATE OF INCORPORATION: NV FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39015 FILM NUMBER: 23707600 BUSINESS ADDRESS: STREET 1: 680 W NYE LANE STREET 2: SUITE 201 CITY: CARSON CITY STATE: NV ZIP: 89703 BUSINESS PHONE: 775-888-3162 MAIL ADDRESS: STREET 1: 680 W NYE LANE STREET 2: SUITE 201 CITY: CARSON CITY STATE: NV ZIP: 89703 FORMER COMPANY: FORMER CONFORMED NAME: NANOANTIBIOTICS, INC. DATE OF NAME CHANGE: 20130625 8-K 1 bivi-20230303_8k.htm CURRENT REPORT
0001580149 false 0001580149 2023-03-02 2023-03-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): March 2, 2023

 

BioVie Inc.
(Exact Name of Registrant as Specified in Its Charter)

 

Nevada   001-39015   46-2510769
(State or Other Jurisdiction
of Incorporation)		   (Commission File Number)   (I.R.S. Employer
Identification No.)
         

680 W Nye Lane Suite 201 

Carson City, NV

   89703
(Address of Principal Executive Offices)   (Zip Code)

 

(775) 888-3162

(Registrant’s Telephone Number, Including Area Code)

 

(Former Name or Former Address, if Changed Since Last Report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Class A Common Stock, par value $0.0001 per share BIVI The Nasdaq Stock Market, LLC

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On March 2, 2023, BioVie Inc. (the “Company”) accepted the resignation of Terren S. Peizer, Chairman of the Board of Directors of the Company (the “Board”), effective immediately, after learning that Mr. Peizer has been separately charged by the Department of Justice and the Securities and Exchange Commission with alleged insider trading of the stock of an unrelated company, Ontrak Inc. Mr. Peizer’s decision to resign is not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. The Board has elected Jim Lang, a current director of the Company, to serve as the new Chairman of the Board, effectively immediately.

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  BIOVIE INC.
     
  By:  /s/ Joanne Wendy Kim
  Name:  Joanne Wendy Kim
  Title: Chief Financial Officer

 

Date: March 3, 2023 

 

 

 EX-101.SCH 2 bivi-20230302.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 bivi-20230302_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 4 bivi-20230302_pre.xml XBRL PRESENTATION FILE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Cover
Mar. 02, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 02, 2023
Entity File Number 001-39015
Entity Registrant Name BioVie Inc.
Entity Central Index Key 0001580149
Entity Tax Identification Number 46-2510769
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 680 W Nye Lane
Entity Address, Address Line Two Suite 201
Entity Address, City or Town Carson City
Entity Address, State or Province NV
Entity Address, Postal Zip Code 89703
City Area Code (775)
Local Phone Number 888-3162
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Class A Common Stock, par value $0.0001 per share
Trading Symbol BIVI
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 6 bivi-20230303_8k_htm.xml IDEA: XBRL DOCUMENT 0001580149 2023-03-02 2023-03-02 iso4217:USD shares iso4217:USD shares 0001580149 false 8-K 2023-03-02 BioVie Inc. NV 001-39015 46-2510769 680 W Nye Lane Suite 201 Carson City NV 89703 (775) 888-3162 Class A Common Stock, par value $0.0001 per share BIVI NASDAQ false false false false false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://bioviepharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports bivi-20230303_8k.htm bivi-20230302.xsd bivi-20230302_lab.xml bivi-20230302_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "bivi-20230303_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "bivi-20230303_8k.htm" ] }, "labelLink": { "local": [ "bivi-20230302_lab.xml" ] }, "presentationLink": { "local": [ "bivi-20230302_pre.xml" ] }, "schema": { "local": [ "bivi-20230302.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "bivi", "nsuri": "http://bioviepharma.com/20230302", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "bivi-20230303_8k.htm", "contextRef": "From2023-03-02to2023-03-02", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://bioviepharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "bivi-20230303_8k.htm", "contextRef": "From2023-03-02to2023-03-02", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 13 0001520138-23-000124-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001520138-23-000124-xbrl.zip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